AdnaGen is a privately held biotechnology research and development
company based in Langenhagen, Germany. AdnaGen was recently acquired by
AdnaGen offers test systems enabling physicians to effect an
individualised treatment of cancer. AdnaGen's core expertise is the
development of innovative tumour diagnostics by utilizing its proprietary
technology for the detection and molecular analysis of circulating tumour
Kits for breast (AdnaTest BreastCancer) and colon (AdnaTest ColonCancer)
as well as an add-on kit for the detection of steroid receptors (AdnaTest
ER/PR) on CTCs are CE-marked and currently marketed in Europe. A kit for the
detection of CTCs in ovarian cancer will be available soon.
Further developments include several molecular markers that reveal the
presence of potential therapeutic targets on CTCs. The analysis of
expression profiles of these markers is also contributing to a better
understanding of the biology of CTCs.
To this end, AdnaGen has developed assays for the determination of
epithelial-mesenchymal transition (EMT) and stem cell markers (patent
pending) that can be used in combination with the AdnaTest BreastCancer.
Clinical results are available that underline the clinical importance of
these markers. AdnaGen is ISO 9001 and EN 13485 certified.